Quantcast

Latest Opioid antagonists Stories

2014-07-09 08:28:33

LONDON, July 9, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production...

2014-06-19 16:26:04

SAN FRANCISCO, June 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, but they also bind to mu-receptors in the bowel. That is why...

2014-06-10 08:29:27

RALEIGH, N.C., June 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two important upcoming healthcare conferences: 34(th) Annual William Blair Growth Stock ConferenceWednesday, June 11, 20143:20 PM Central Time (4:20 PM Eastern Time)Four Seasons Hotel, Chicago, IL Wells Fargo 2014 Healthcare ConferenceTuesday, June 17, 20144:40 PM Eastern...

2014-06-06 23:01:17

A nasal-spray version of Naloxone, a heroin/opiate overdose-reversal drug, is in the works in Kentucky. (PRWEB) June 06, 2014 As reported by USA Today in the article Nasal Spray For Heroin Antidote Under Development(5/31), a Kentucky doctor has been successful in advocating a nasal spray medicine to reverse a heroin or opiate overdose. Dr. Daniel Wermeling has made a deal with a pharmaceutical company to create a nasal spray version of naloxone, a common medicine used on persons who are...

2014-06-05 13:33:09

University of Michigan Health System With naloxegol, adults found relief from opioid-induced constipation Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System. Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Laxatives provide sub-optimal relief. The...

2014-05-19 08:28:11

RICHMOND, Va., May 19, 2014 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. (RBP) announced today that it has entered into a definitive agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval. The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin - a growing...

2014-05-08 08:31:55

RALEIGH, N.C., May 8, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2014 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) at Encore at Wynn in Las Vegas. The New Drug Application (NDA) for BUNAVAIL for the treatment of opioid dependence is...

2014-05-06 23:17:29

Passages Malibu CEO comments on enhanced access to treatment in the US. Malibu, CA (PRWEB) May 06, 2014 On April 3rd, the Food and Drug Administration announced its approval of Evzio, an antidote to opiate overdose. The medication was designed to be easily administered by family members or caregivers via an auto-injector. Evzio contains naloxone, which has proven valuable in the fight to save people from heroin and opiate overdose. An overdose of opiates is generally characterized by...

2014-03-11 16:26:19

PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including...

2014-03-05 08:28:31

RALEIGH, N.C., March 5, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 26(th) Annual ROTH Conference. The presentation is scheduled for Monday, March 10, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel in Dana Point, California. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The New Drug Application...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.